Eledon Pharmaceuticals, Inc (ELDN)

Etorro trading 970x250
Eledon Pharmaceuticals, Inc (ELDN) Logo

About Eledon Pharmaceuticals, Inc

Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company’s lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Address: 19900 MacArthur Boulevard, Irvine, CA, United States, 92612

Eledon Pharmaceuticals, Inc News and around…

Latest news about Eledon Pharmaceuticals, Inc (ELDN) common stock and company :

2 “Strong Buy” Penny Stocks That Could See Outsized Gains
13 Jan, 2022 Yahoo! Finance

For investors seeking the strongest possible returns, there has always been a clear path. It involves risk, but the rewards are real. We’re talking, of course, about the outsized gains available in penny stocks, the low-priced equities that can slide under the radar. Historically, these are shares that sold for less than an old English shilling – just pennies. Later, they were defined as stocks selling for less than a one dollar per share; today, they’re the shares priced at less than $5. No mat

12 Health Care Stocks Moving In Tuesday's After-Market Session
04 Jan, 2022 FinancialContent

Gainers Oncternal Therapeutics (NASDAQ:ONCT) stock increased by 15.8% to $2.71 during Tuesday's after-market session. Trading volume ...

Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences
27 Dec, 2021 Yahoo! Finance

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences: Event:LifeSci Partners Corporate Access Event (January 5-7, 2022)F

IWC's Holdings Imply 45% Gain Potential
27 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $203.66 per unit.

A number of insiders bought Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock last year, which is great news for shareholders
24 Dec, 2021 Yahoo! Finance

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

70 Biggest Movers From Friday
15 Nov, 2021 FinancialContent

Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported ...

12 Health Care Stocks Moving In Friday's Intraday Session
12 Nov, 2021 FinancialContent

Gainers SOC Telemed (NASDAQ:TLMD) stock increased by 30.04% to $2.77 during Friday's regular session. The current ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Nov, 2021 FinancialContent

Gainers Sundial Growers (NASDAQ:SNDL) stock increased by 28.49% to $0.93 during Friday's pre-market session. The ...

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
12 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its ...

Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results
11 Nov, 2021 Yahoo! Finance

Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022 Received Investigational New Drug (“IND”) clearance from the FDA for AT-1501 in islet cell transplantation in the U.S. Announced renal transplantation research collaboration with CareDx, Inc. Initiated AT-1501 monotherapy non-human primate renal transplant study; topline data expected 1H 2022 Conference call today at 4:30 PM ET IRVINE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NAS

The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
11 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus MerckCommences ...

Earnings Scheduled For November 11, 2021
11 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on ...

Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021
04 Nov, 2021 Yahoo! Finance

Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon’s investigational AT-1501 for the prevention of rejection in upcoming kidney transplantation trialsIRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune di

Eledon Pharmaceuticals Announces Participation in November Conferences
04 Nov, 2021 Yahoo! Finance

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that members of management will be participating in two upcoming virtual investor conferences in November. Event:Guggenheim 3rd Annual Neuro/Immunology C

Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021
01 Nov, 2021 Yahoo! Finance

Management to host conference call and webcast at 4:30 pm ETIRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that it plans to release financial results for the third quarter ended September 30,

CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement
19 Oct, 2021 Yahoo! Finance

Eledon to use AlloSure to help assess the efficacy of AT-1501 in the prevention of rejection in Eledon’s upcoming renal transplantation trialsSOUTH SAN FRANCISCO, Calif. and IRVINE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, and Eledon Pharmaceuticals, Inc. (“Eledon”) (Na

Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium
07 Oct, 2021 Yahoo! Finance

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced their participation in the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) which is being held virtually on October 7, 2021. Dr. Steve Perrin, Eledo

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress
05 Oct, 2021 Yahoo! Finance

IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced an upcoming presentation on AT-1501, its lead clinical candidate, at the International Pancreas and Islet Transplantation Association (IPITA) Congress, which i

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Eledon Pharmaceuticals to Present at Two Investor Conferences in September
01 Sep, 2021 FinancialContent
How The Parts Add Up: ITOT Targets $112
19 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results
12 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
02 Aug, 2021 FinancialContent

Management to host conference call and webcast at 4:30 pm ET

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation
26 Jul, 2021 FinancialContent

Eledon Pharmaceuticals, Inc (ELDN) is a NASDAQ Common Stock listed in , ,

970x250